MiR-320a downregulation is associated with imatinib resistance in gastrointestinal stromal tumors

Gao, Xiaodong; Shen, Kuntang; Wang, Cuizhong; Ling, Jiaqian; Wang, Hongshan; Fang, Yong; Shi, Yuan; Hou, Yingyong; Qin, Jin; Sun, Yihong; Qin, Xinyu
January 2014
Acta Biochimica et Biophysica Sinica;Jan2014, Vol. 46 Issue 1, p72
Academic Journal
Gastrointestinal stromal tumor (GIST) is one of the most common mesenchymal tumors of the gastrointestinal tract. Though imatinib improves the outcome, drug resistance remains the major problem for extending patient survival. Genetic mutation of the drug targets is the known mechanism for imatinib resistance. However, it cannot explain all of the phenomena of imatinib resistance, and numerous additional mechanisms have been proposed to account for imatinib resistance in various model systems. In this study, we applied the SYBR-green quantitative polymerase chain reaction-based array approach to screen the differentially expressed miRNAs between primary GIST patients and imatinib-resistant patients. The selected candidate miRNAs were validated in a cohort of 12 GIST patients. We found that low expression of miR-320a was correlated with short time to imatinib resistance, and proposed the potential mechanism of miR-320a for imatinib resistance.


Related Articles

  • Double resistance to imatinib and AMG 706 caused by multiple acquired KIT exon 17 mutations in a gastrointestinal stromal tumour. Grabellus, Florian; Ebeling, Peter; Worm, Karl; Sien-Yi Sheu; Antoch, Gerald; Frilling, Andrea; Schmid, Kurt W. // Gut;Jul2007, Vol. 56 Issue 7, p1025 

    A letter to the editor is presented regarding the resistance of a gastrointestinal stromal tumor case to imatinib.

  • Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. Catania, Chiara; Conforti, Fabio; Spitaleri, Gianluca; Barberis, Massimo; Preda, Lorenzo; Noberasco, Cristina; Lazzari, Chiara; Toffalorio, Francesca; de Marinis, Filippo; Manzotti, Michela; De Pas, Tommaso Martino // OncoTargets & Therapy;2014, Vol. 7, p697 

    We report the case of a man with an advanced nonkeratinizing squamous cell thymic carcinoma harboring c-KIT exon 13 missense mutation K642E. This aberration is rare and has never been described previously in patients with thymic cancers. It has been found in a small number of cases of...

  • Imatinib.  // Reactions Weekly;Sep2014, Vol. 1518 Issue 1, p97 

    An abstract of the article "Long-term survival after excision of a giant esophageal gastrointestinal stromal tumor with imatinib mesylate resistance: Report of a case," by S. Takeno and colleagues is presented.

  • Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors. Edris, Badreddin; Willingham, Stephen; Weiskopf, Kipp; Volkmer, Anne K.; Volkmer, Jens-Peter; Mühlenberg, Thomas; Weissman, Irving L.; van de Rijn, Matt // OncoImmunology;Jun2013, Vol. 2 Issue 6, pe24452-1 

    Acquired resistance to imatinib is a significant problem for the clinical management of gastrointestinal stromal tumor (GIST ) patients, and second-line small molecules have shown limited efficacy in this setting. We have recently demonstrated that a monoclonal antibody targeting KIT could...

  • Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene. Yamaguchi, Masahiko; Matsumoto, Tadashi; Tate, Genshu; Higuchi, Takakazu // Journal of Gastroenterology;2004, Vol. 39 Issue 9, p904 

    Presents a letter to the editor about the clinical and radiographic responses to imatinib mesylate in a patient with unresectable gastrointestinal stromal tumors.

  • Imatinib.  // Reactions Weekly;Oct2014, Vol. 1523 Issue 1, p114 

    An abstract of the article "Facial hyperpigmentation during imatinib therapy for gastrointestinal stromal tumor" by I. Hamza and colleagues is presented.

  • Imatinib.  // Reactions Weekly;Jan2015, Vol. 1533 Issue 1, p254 

    An abstract of the article "Early onset imatinib mesylate-induced hepatotoxicity in a patient with gastrointestinal stromal tumors," by R. Yachoui is presented.

  • Imatinib.  // Reactions Weekly;8/4/2012, Issue 1413, p26 

    The article describes the case of a man who developed a lichenoid drug eruption during treatment with imatinib for gastrointestinal stromal tumors.

  • Dermatitis after suspected imatinib–levothyroxine interaction in a patient with gastrointestinal stromal tumor. Cholongitas, Evangelos; Pipili, Chrysoula; Katsogridakis, Konstadinos; Relos, Konstadinos; Dasenaki, Maria // Cancer Chemotherapy & Pharmacology;May2008, Vol. 61 Issue 6, p1083 

    A letter to the editor is presented regarding dermatitis after suspected imatinib-levothyroxine interaction in a patient with gastrointestinal stromal tumor.

  • Neoadjuvant Treatment of Rectal Gastrointestinal Stromal Tumors with Imatinib. Turner, Jacquelyn; Batus, Marta; Leslie, William; Coogan, Christopher; Saclarides, Theodore J. // American Surgeon;Aug2010, Vol. 76 Issue 8, pE110 

    A letter to the editor is presented which is concerned with two patients with gastrointestinal stromal tumors who were treated with imatinib.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics